pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Phase 2 · small molecule · Glioblastoma
Lomustine "medac" 40 mg (GLEOSTINE) is an oral small-molecule alkylating agent approved by the FDA and currently being evaluated in a Phase 2 dose optimization study by Philogen S.p.A. The program, designated PH-L19TNFLOM-01/23, investigates lomustine in combination with L19TNF in patients with glioblastoma at progress
Internal code PH-L19TNFLOM-01/23
Lomustine "medac" 40 mg (GLEOSTINE) is an oral small-molecule alkylating agent approved by the FDA and currently being evaluated in a Phase 2 dose optimization study by Philogen S.p.A. The program, designated PH-L19TNFLOM-01/23, investigates lomustine in combination with L19TNF in patients with glioblastoma at progression or recurrence. Lomustine is an established chemotherapy with a long clinical history; the current study focuses on optimizing dosing when combined with an investigational TNF-based immunotherapy. Philogen's strategy appears to center on combination approaches to enhance efficacy in recurrent/progressive glioblastoma, a disease with limited treatment options and poor prognosis. The program remains in active Phase 2 development with no regulatory filing or approval yet disclosed for this specific combination. Key milestones will include Phase 2 data readout and potential advancement to Phase 3, though timelines are not yet disclosed.
Glioblastoma remains one of the most aggressive and difficult-to-treat human malignancies, with median overall survival of approximately 15 months despite standard-of-care Stupp protocol (radiotherapy plus temozolomide). Recurrent and progressive disease carries an even poorer prognosis, with limited effective salvage options. Current standard therapies include surgical resection, radiation modalities (stereotactic, GammaTile implantation), and chemotherapy (temozolomide, lomustine). The combination of lomustine with L19TNF represents a potential dual-mechanism approach: cytotoxic chemotherapy plus TNF-mediated immunotherapy and vascular targeting. This addresses a significant unmet medical need in the recurrent/progressive setting where patient outcomes remain dismal. The competitive landscape includes multiple Phase 3 programs (temozolomide combinations, enzastaurin, edotecarin, cediranib, and other lomustine-based regimens), indicating active industry focus on this indication. Philogen's approach differentiates through its immunotherapy component, potentially offering a novel mechanism to overcome chemotherapy resistance. Commercial significance is substantial given the high mortality rate and limited effective options, though the patient population is relatively small compared to other oncology indications.
Drug Class: Alkylating agent (nitrosourea); established small-molecule chemotherapy.
Modality: Small molecule.
Route of Administration: Oral.
Mechanism of Action: Not disclosed in available facts; however, lomustine is a DNA-alkylating agent that cross-links DNA strands, leading to cell death.
Target: Not disclosed in available facts.
Related Therapies: Temozolomide (oral alkylating agent, widely used in glioblastoma); other nitrosoureas; combination with L19TNF (investigational TNF-immunotherapy).
Regulatory Status: Lomustine (GLEOSTINE) is FDA-approved; current approvals held by Azurity and Carnegie Pharma (ANDA219265, NDA017588).
Patent Status: Not disclosed in available facts.
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
ClinicalTrials.gov lists 877 registered studies for Glioblastoma (AACT aggregate).
Phase breakdown: NA (252), PHASE2 (223), PHASE1 (206), PHASE1/PHASE2 (86), EARLY_PHASE1 (49), PHASE3 (45), PHASE2/PHASE3 (11), PHASE4 (5)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018177), Orphanet — glioblastoma, NCT00001148, NCT00001171, NCT00009035, NCT00028158, NCT00029783, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Dose optimization study ongoing
Phase 2 dose optimization study for L19TNF in combination with lomustine in patients with glioblastoma at progression or recurrence (NCT 2024-515609-25-00).
The glioblastoma treatment landscape includes established standard-of-care therapies (Stupp protocol with temozolomide, surgical resection, stereotactic and GammaTile radiation) and multiple investigational programs in Phase 3 development. Temozolomide-based combinations are being evaluated by Adaptive Biotechnologies Corp and Novo Nordisk A/S (including with Keytruda). Lomustine monotherapy is also in Phase 3 development by Lacuna Pharma Pty Ltd and Ningbo Cancer Hospital. Small-molecule kinase inhibitors in Phase 3 include enzastaurin (Eli Lilly), edotecarin (Pfizer), and cediranib (AstraZeneca). Philogen's combination of lomustine with L19TNF (an investigational TNF-immunotherapy with vascular targeting properties) differentiates through its dual mechanism: cytotoxic chemotherapy plus immunotherapy. This approach is distinct from most competitors, which focus on single-agent or chemotherapy-plus-checkpoint-inhibitor combinations. However, the program remains in Phase 2 while multiple competitors have advanced to Phase 3, indicating a potential competitive timing disadvantage. The recurrent/progressive glioblastoma setting remains underserved, providing opportunity for differentiated approaches.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Stereotactic Radiation Therapy | GT Biopharma | other | approved |
| IRON OXIDE (E172) | Disc Medicine | small_molecule | approved |
| Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide) | GT Biopharma | other | approved |
| Temozolomide | Adaptive Biotechnologies Corp | small_molecule | phase_3 |
| enzastaurin | Eli Lilly and Company | small_molecule | phase_3 |
| Edotecarin | Pfizer | small_molecule | phase_3 |
| LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| ADI-PEG-20, Troriluzole, AZD1390 | Adaptive Biotechnologies Corp | small_molecule | phase_3 |
| TEMOZOLOMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, saline solution for infusion | Novo Nordisk A/S | small_molecule | phase_3 |
| Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| Cediranib | AstraZeneca | small_molecule | phase_3 |
| LOMUSTINE | Ningbo Cancer Hospital | small_molecule | phase_3 |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 3 |
| RINDOPEPIMUT | — | Epidermal growth factor receptor erbB1 vaccine antigen | Phase 3 |
| OMBIPEPIMUT-S | — | Wilms tumor protein vaccine antigen | Phase 3 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 3 |
| NIMOTUZUMAB | — | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Lomustine (GLEOSTINE) is FDA-approved; current approvals held by Azurity Pharmaceuticals (ANDA219265) and Carnegie Pharma (NDA017588). The combination of lomustine with L19TNF has not yet received FDA approval or filing status disclosure.
EMA Status: Not yet disclosed in available facts.
PMDA (Japan) Status: Not yet disclosed in available facts.
NMPA (China) Status: Not yet disclosed in available facts.
Development Status: The combination program is in Phase 2; no regulatory pathway designation (breakthrough therapy, fast track, orphan drug) has been disclosed.
Lomustine (GLEOSTINE) is an FDA-approved alkylating chemotherapy agent used in cancer treatment, including glioblastoma. In this program, it is being studied in combination with L19TNF for glioblastoma at progression or recurrence.
Yes, lomustine (GLEOSTINE) is FDA-approved. Current approvals are held by Azurity Pharmaceuticals (ANDA219265) and Carnegie Pharma (NDA017588).
Lomustine is a nitrosourea alkylating agent that cross-links DNA strands, leading to cell death. Specific molecular targets are not disclosed in available facts.
Philogen S.p.A. is the sponsor of the lomustine and L19TNF combination program (internal code PH-L19TNFLOM-01/23).
The indication is glioblastoma, specifically in patients at progression or recurrence.
The program is in Phase 2, conducting a dose optimization study for the combination.
Lomustine is administered orally as a 40 mg formulation ("medac").
L19TNF is an investigational immunotherapy being combined with lomustine in this program. Specific details regarding its mechanism and development status are not disclosed in available facts.
The trial identifier is NCT 2024-515609-25-00.
Primary endpoints for the Phase 2 dose optimization study have not yet been disclosed in available facts.
The program is active in Phase 2 development; no regulatory filing or approval has been disclosed.
Competitors include standard-of-care therapies (Stupp protocol with temozolomide, surgery, radiation) and multiple Phase 3 programs including temozolomide combinations, enzastaurin, edotecarin, cediranib, and other lomustine-based regimens.
No development partner is disclosed in available facts; Philogen S.p.A. is listed as the sole sponsor.
Recurrent and progressive glioblastoma carries poor prognosis with limited effective salvage options; median survival is approximately 15 months or less, representing a significant unmet medical need.
The patient population is individuals with glioblastoma at progression or recurrence, representing a subset of glioblastoma patients with particularly poor prognosis.
Expected next milestones are not yet disclosed in available facts; Phase 2 data readout and potential Phase 3 advancement would be anticipated catalysts.
Lomustine "medac" 40 mg, Fibromun → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Philogen's approach combines an established chemotherapy (lomustine) with an investigational immunotherapy (L19TNF), potentially addressing chemotherapy resistance through dual mechanisms. This represents a rational combination strategy in a disease with poor prognosis and limited salvage options.
Competitive Implications: The program faces significant competition from multiple Phase 3 programs, particularly temozolomide-based combinations and other small-molecule approaches. Philogen's immunotherapy component offers potential differentiation, but Phase 2 status places it behind competitors. Success will depend on demonstrating superior efficacy or tolerability compared to existing options.
Key Catalysts: Phase 2 data readout will be critical; positive results could support Phase 3 advancement. Regulatory feedback on trial design and endpoints will influence development trajectory. Competitive data from Phase 3 programs may impact strategic decisions.
Development Risks: Glioblastoma trials are historically challenging due to small patient populations, heterogeneous disease biology, and high failure rates. The combination approach introduces complexity in dose optimization and safety monitoring. Timing relative to Phase 3 competitors is a concern.
Future Milestones: Phase 2 data presentation/publication; potential Phase 3 initiation; regulatory interactions regarding trial design; competitive data readouts from Phase 3 programs.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.